Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience

Annalisa Trama, Claudia Proto, Jennifer G. Whisenant, Valter Torri, Alessio Cortellini, Olivier Michielin, Fabrice Barlesi, Anne-Marie C. Dingemans, Jan Van Meerbeeck, Vera Pancaldi, Julien Mazieres, Ross A. Soo, Natasha B. Leighl, Solange Peters, Heather Wakelee, Leora Horn, Matthew Hellmann, Selina K. Wong, Marina Chiara Garassino*, Javier Baena

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

6 Citations (Web of Science)


To understand the real impact of COVID-19 on cancer patients, an entirely new data collection effort was initiated within the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT). TERAVOLT reported high mortality related to COVID-19 infection in thoracic cancer patients and identified several negative prognostic factors. In this commentary, we discuss the importance and limits of patient registries to support decision-making in thoracic cancer during the SARS-CoV-2 pandemic.

Original languageEnglish
Pages (from-to)602-604
Number of pages3
JournalCancer Cell
Issue number5
Publication statusPublished - 9 Nov 2020


  • COVID-19

Cite this